Latest News from: Dana-Farber Cancer Institute

Filters close
Newswise: A case of reverse development: Dana-Farber scientists solve long-debated puzzle of how the intestine heals itself
Released: 19-Feb-2020 3:45 PM EST
A case of reverse development: Dana-Farber scientists solve long-debated puzzle of how the intestine heals itself
Dana-Farber Cancer Institute

Scientists find that normal intestinal cells “de-differentiate” en masse into stem cells that generate the cells needed for a healthy intestinal lining. New study establishes de-differentiation as the predominant mode of stem cell recover in the intestine

Newswise: Novel targeted drug shows promise in advanced kidney cancer
Released: 13-Feb-2020 12:45 PM EST
Novel targeted drug shows promise in advanced kidney cancer
Dana-Farber Cancer Institute

Scientists report promising activity of a novel drug that targets a key molecular driver of clear cell renal cell carcinoma (ccRCC) in patients with metastatic disease.

Released: 11-Feb-2020 10:00 AM EST
Dana-Farber Cancer Institute provides state-of-the-art oncology support services to Kronos employees through new company benefit
Dana-Farber Cancer Institute

Dana-Farber Cancer Institute and Kronos Incorporated have joined forces to provide dedicated oncology care navigation services via a new benefit for Kronos employees and their beneficiaries.

Newswise: Dozens of potential anti-cancer drugs netted in massive screening study
Released: 19-Jan-2020 11:05 AM EST
Dozens of potential anti-cancer drugs netted in massive screening study
Dana-Farber Cancer Institute

A variety of existing drugs for treating conditions such as diabetes, inflammation, alcohol abuse, and arthritis in dogs can also kill cancer cells in the lab, according to a study by scientists at Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard.

Newswise: Dana-Farber Cancer Institute to Establish Riney Family Multiple Myeloma Initiative
Released: 13-Jan-2020 9:00 AM EST
Dana-Farber Cancer Institute to Establish Riney Family Multiple Myeloma Initiative
Dana-Farber Cancer Institute

Dana-Farber Cancer Institute will establish the Riney Family Multiple Myeloma Initiative to help improve outcomes and accelerate understanding of the underlying biology for the most challenging types of myelomas, cancers that form in a type of white blood cell called a plasma cell.

Newswise: Dana-Farber Cancer Institute to Establish Chen-Huang Center for EGFR Mutant Lung Cancers
Released: 3-Jan-2020 3:55 PM EST
Dana-Farber Cancer Institute to Establish Chen-Huang Center for EGFR Mutant Lung Cancers
Dana-Farber Cancer Institute

Dana-Farber Cancer Institute will create the Chen-Huang Center for EGFR (epidermal growth factor receptor) Mutant Lung Cancers to stimulate research, promote clinical trials, and strengthen the Institute’s capabilities for studying and treating lung cancer.

Newswise: Treatment with PD-1 inhibitor prior to stem cell transplant is safe, effective for patients with classic Hodgkin lymphoma, study finds
Released: 26-Nov-2019 5:05 PM EST
Treatment with PD-1 inhibitor prior to stem cell transplant is safe, effective for patients with classic Hodgkin lymphoma, study finds
Dana-Farber Cancer Institute

A new analysis shows that a donor stem cell transplant following treatment with an immune checkpoint inhibitor is generally safe and produces good outcomes for patients with Hodgkin lymphoma.

Newswise: Dana-Farber scientists present promising findings in multiple myeloma at ASH Annual Meeting
Released: 6-Dec-2019 8:30 AM EST
Dana-Farber scientists present promising findings in multiple myeloma at ASH Annual Meeting
Dana-Farber Cancer Institute

Results of studies on a novel agent to treat multiple myeloma and a combination therapy aimed at slowing the progression of a precursor myeloma condition are among reports being presented by Dana-Farber Cancer Institute investigators at the ASH Annual Meeting.

Newswise: Use of venetoclax in reduced-intensity transplant conditioning regimen in patients with high-risk myeloid cancers shows promise in early trial
Released: 5-Dec-2019 12:05 PM EST
Use of venetoclax in reduced-intensity transplant conditioning regimen in patients with high-risk myeloid cancers shows promise in early trial
Dana-Farber Cancer Institute

For patients with high-risk myeloid cancers undergoing a donor stem cell transplant, adding the targeted drug venetoclax to a reduced-intensity drug regimen prior to transplant is safe and does not impair the ability of the donor cells to take root in recipients’ bodies, a study led by Dana-Farber Cancer Institute researchers suggests.

Newswise: Genomic features of AML in patients over age 60 can predict success of bone marrow stem cell transplant, research shows
Released: 6-Dec-2019 8:30 AM EST
Genomic features of AML in patients over age 60 can predict success of bone marrow stem cell transplant, research shows
Dana-Farber Cancer Institute

For older patients with acute myeloid leukemia (AML), the prospects for success of a stem cell transplant can often be predicted based on the particular set of genetic mutations within the tumor cells, investigators at Dana-Farber Cancer Institute and other research centers will report today at the ASH Annual Meeting.



close
0.19489